Reply to: Prostate‐specific membrane antigen‐PET‐defined oligoprogressive castration‐resistant prostate cancer: is metastasis‐directed therapy ready for prime time?
Tobias Hölscher, Fabian Lohaus. Reply to: Prostate‐specific membrane antigen‐PET‐defined oligoprogressive castration‐resistant prostate cancer: is metastasis‐directed therapy ready for prime time?. // BJU International. – 2026. – DOI: 10.1111/bju.70494. – URL: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.70494?af=R
Tobias Hölscher & Fabian Lohaus (2026). Reply to: Prostate‐specific membrane antigen‐PET‐defined oligoprogressive castration‐resistant prostate cancer: is metastasis‐directed therapy ready for prime time?. BJU International. https://doi.org/10.1111/bju.70494
Tobias Hölscher and Fabian Lohaus. “Reply to: Prostate‐specific membrane antigen‐PET‐defined oligoprogressive castration‐resistant prostate cancer: is metastasis‐directed therapy ready for prime time?.” BJU International, 2026. doi:10.1111/bju.70494.
@article{Hlscher2026,
title = {Reply to: Prostate‐specific membrane antigen‐PET‐defined oligoprogressive castration‐resistant prostate cancer: is metastasis‐directed therapy ready for prime time?},
author = {Hölscher, Tobias and Lohaus, Fabian},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70494},
url = {https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.70494?af=R}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...